Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: J Geriatr Oncol. 2018 Apr 17;9(4):321–328. doi: 10.1016/j.jgo.2018.03.018

Fig. 2.

Fig. 2

CART results for patients with CLL receiving only biologic therapy. Patients with CLL were partitioned into subgroups (based on PS ≥1 vs. PS <1) across which the probability of experiencing a grade three or four toxicity may differ.